查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1618144

氣體交換肺功能測試市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032 年

Gas Exchange Pulmonary Function Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球氣體交換肺功能測試市場價值達到2.385 億美元，預計2024 年至2032 年複合年成長率將穩定在5.8%。和治療疾病。透過評估擴散能力，氣體交換測試提供了肺功能的重要見解，有助於制定客製化的治療策略和有效的疾病管理。旨在增強呼吸系統健康的政府措施不斷增多，正在顯著推動市場成長。專注於呼吸系統疾病預防的政策，加上對早期檢測和預防性醫療保健的日益重視，將氣體交換肺部測試定位為呼吸系統健康管理的重要工具。

市場分為攜帶式和固定式系統，攜帶式設備預計將以6% 的複合年成長率成長，到2032 年將超過3.29 億美元。 ，刺激了對攜帶式設備的需求測試解決方案。攜帶式設備可以在傳統醫療機構之外進行測試，提高患者的便利性，並使醫療保健提供者在各種環境下具有更大的適應性。技術進步進一步推動了攜帶式肺功能測試 (PFT) 設備的採用，提高了準確性和易用性。就測試方法而言，市場分為氣體擴散測試和心肺運動測試（CPET）。

氣體擴散測試領域在 2023 年佔據主導地位，佔 61.2% 的市場佔有率，這得益於其在影響肺泡毛細血管膜上氧氣和二氧化碳交換的條件下診斷和追蹤肺功能的有效性。這種方法對於檢測早期肺損傷至關重要，對於慢性呼吸道疾病患者至關重要。氣體擴散測試提供有關肺部效率的精確資料，以管理損害呼吸功能的疾病。北美市場到2023 年將產生9,650 萬美元的收入，預計到2032 年將保持複合年成長率5.2% 的成長。的治療結果並減少再入院率。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 2.385 億美元
預測值 3.92 億美元
複合年成長率 5.8%

促進定期監測慢性肺部疾病的醫療保健政策推動了對肺功能檢測的需求。此外，醫療保健行業向基於價值的護理的轉變強調預防措施，並支持常規肺功能評估。對主動呼吸護理的日益關注加強了北美作為市場擴張主要貢獻者的作用。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 呼吸道疾病盛行率上升
      • 技術進步
      • 擴大新興市場的醫療保健基礎設施
    • 產業陷阱與挑戰
      • 設備成本高
  • 成長潛力分析
  • 監管環境
  • 報銷場景
  • 技術景觀
  • 差距分析
  • 波特的分析
  • PESTEL分析
  • 價值鏈分析
  • 未來市場趨勢

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按系統類型，2021 - 2032 年

  • 主要趨勢
  • 便攜的
  • 固定式

第 6 章：市場估計與預測：按測試方法，2021 - 2032 年

  • 主要趨勢
  • 氣體擴散測試
  • 心肺運動試驗（CPET）

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 慢性阻塞性肺病（COPD）
  • 氣喘
  • 慢性呼吸短促
  • 肺纖維化
  • 其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院和診所
  • 診斷中心
  • 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • CHEST
  • COSMED
  • ECO MEDICS
  • Geratherm Medical
  • KoKo PFT
  • Koninklijke Philips
  • MGC Diagnostics Corporation
  • ndd Medical Technologies
  • PulmOne
  • SCHILLER
  • Vitalograph
  • Vyaire Medical
簡介目錄
Product Code: 11737

The Global Gas Exchange Pulmonary Function Testing Market reached a value of USD 238.5 million in 2023, with projections for a steady 5.8% CAGR from 2024 to 2032. This market primarily evaluates lung efficiency in transferring oxygen to the bloodstream and expelling carbon dioxide to diagnose and manage respiratory conditions like COPD and asthma. By assessing diffusion capacity, gas exchange testing provides critical insights into lung function, aiding in tailored treatment strategies and effective disease management. Increasing government initiatives aimed at enhancing respiratory health are significantly driving market growth. Policies focused on respiratory disease prevention, coupled with a rising emphasis on early detection and preventive healthcare, are positioning gas exchange pulmonary testing as a vital tool in respiratory health management.

The market is divided into portable and stationary systems, with portable devices projected to grow at a 6% CAGR and surpass USD 329 million by 2032. The need for flexible and accessible diagnostics, particularly with the rise in respiratory diseases, has fueled demand for portable testing solutions. Portable devices enable testing outside traditional healthcare facilities, improving patient convenience and allowing healthcare providers greater adaptability in various settings. Advances in technology have further boosted the adoption of portable pulmonary function test (PFT) devices, facilitating enhanced accuracy and ease of use. In terms of test methods, the market is segmented into gas diffusion tests and cardiopulmonary exercise testing (CPET).

The gas diffusion test segment dominated with a 61.2% market share in 2023, driven by its effectiveness in diagnosing and tracking lung function in conditions that impact oxygen and carbon dioxide exchange across the alveolar-capillary membrane. This method is crucial for detecting early lung damage, proving essential for patients with chronic respiratory diseases. Gas diffusion tests provide precise data on lung efficiency for managing diseases that impair respiratory function. The North American market, generating USD 96.5 million in revenue in 2023, is expected to maintain growth with a 5.2% CAGR through 2032. Regional growth is supported by government-led initiatives to improve outcomes for patients with respiratory conditions and reduce hospital readmissions.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$238.5 Million
Forecast Value$392 Million
CAGR5.8%

Healthcare policies promoting regular monitoring for chronic lung diseases drive the demand for pulmonary function testing. Furthermore, the healthcare industry's shift towards value-based care emphasizes preventive measures, supporting routine lung function assessments. This growing focus on proactive respiratory care reinforces North America's role as a major contributor to the market's expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of respiratory diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Expansion of healthcare infrastructure in emerging markets
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with equipment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Technology landscape
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Value chain analysis
  • 3.11 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By System Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Portable
  • 5.3 Stationary

Chapter 6 Market Estimates and Forecast, By Test Method, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Gas diffusion tests
  • 6.3 Cardiopulmonary exercise testing (CPET)

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Chronic obstructive pulmonary disease (COPD)
  • 7.3 Asthma
  • 7.4 Chronic shortness of breath
  • 7.5 Pulmonary fibrosis
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals & clinics
  • 8.3 Diagnostic centers
  • 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 CHEST
  • 10.2 COSMED
  • 10.3 ECO MEDICS
  • 10.4 Geratherm Medical
  • 10.5 KoKo PFT
  • 10.6 Koninklijke Philips
  • 10.7 MGC Diagnostics Corporation
  • 10.8 ndd Medical Technologies
  • 10.9 PulmOne
  • 10.10 SCHILLER
  • 10.11 Vitalograph
  • 10.12 Vyaire Medical